The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness

  • Jie Liu (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Shuang Li (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Fan Yang (Department of Nephrology, Beijing Aerospace General Hospital) ;
  • Tianyu Li (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Rui Li (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Yousuf Waheed (Department of Nephrology, Affiliated Hospital of Xuzhou Medical University) ;
  • Chen Meng (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Shulin Li (Department of Nephrology, Affiliated Hospital of Xuzhou Medical University) ;
  • Kun Liu (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Yanshan Tong (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Haisheng Xu (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Chuankuo Tian (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Xinglei Zhou (Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University)
  • Received : 2023.11.27
  • Accepted : 2024.02.20
  • Published : 2024.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background/Aims: Roxadustat, an oral medication for treating renal anemia, is a hypoxia-inducible factor prolyl hydroxylase inhibitor used for regulating iron metabolism and promoting erythropoiesis. To investigate the efficacy and safety of roxadustat in patients undergoing peritoneal dialysis (PD) with erythropoietin hyporesponsiveness. Methods: Single-center, retrospective study, 81 PD patients (with erythropoietin hyporesponsiveness) were divided into the roxadustat group (n = 61) and erythropoiesis-stimulating agents (ESAs) group (n = 20). Hemoglobin (Hb), total cholesterol, intact parathyroid hormone (iPTH), brain natriuretic peptide (BNP), related indicators of cardiac function and high-sensitivity C-reactive protein (hs-CRP) were collected. Additionally, adverse events were also recorded. The follow-up period was 16 weeks. Results: The two groups exhibited similar baseline demographic and clinical characteristics. At baseline, the roxadustat group had a mean Hb level of 89.8 ± 18.9 g/L, while the ESAs group had a mean Hb level of 95.2 ± 16.0 g/L. By week 16, the Hb levels had increased to 118 ± 19.8 g/L (p < 0.05) in the roxadustat group and 101 ± 19.3 g/L (p > 0.05) in the ESAs group. The efficacy of roxadustat in improving anemia was not influenced by baseline levels of hs-CRP and iPTH. Cholesterol was decreased in the roxadustat group without statin use. An increase in left ventricular ejection fraction and stabilization of BNP were observed in the roxadustat group. Conclusions: For PD patients with erythropoietin hyporesponsiveness, roxadustat can significantly improve renal anemia. The efficacy of roxadustat in improving renal anemia was not affected by baseline levels of hs-CRP0 and iPTH.

Keywords

Acknowledgement

We would like to express our sincere thanks to every member of our research team for their hard-work and the strong support provided by the hospital.

References

  1. Toft G, Heide-Jorgensen U, van Haalen H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J Nephrol 2020;33:147-156.  https://doi.org/10.1007/s40620-019-00652-9
  2. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004;65:1864-1869.  https://doi.org/10.1111/j.1523-1755.2004.00584.x
  3. Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol 2017;13:90-103.  https://doi.org/10.1038/nrneph.2016.181
  4. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007;12:321-330.  https://doi.org/10.1111/j.1440-1797.2007.00810.x
  5. Ogawa T, Nitta K. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients. Contrib Nephrol 2015;185:76-86.  https://doi.org/10.1159/000380972
  6. Singh AK, Carroll K, McMurray JJV, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med 2021;385:2313-2324.  https://doi.org/10.1056/NEJMoa2113380
  7. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56.  https://doi.org/10.1053/j.ajkd.2012.07.014
  8. Del Vecchio L, Minutolo R. ESA, iron therapy and new drugs: are there new perspectives in the treatment of anaemia? J Clin Med 2021;10:839. 
  9. Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 2017;69:815-826.  https://doi.org/10.1053/j.ajkd.2016.12.011
  10. Akizawa T, Yamaguchi Y, Otsuka T, Reusch M. A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naive chronic kidney disease patients not on dialysis. Nephron 2020;144:372-382.  https://doi.org/10.1159/000508100
  11. Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 2019;381:1011-1022.  https://doi.org/10.1056/NEJMoa1901713
  12. Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 2019;381:1001-1010.  https://doi.org/10.1056/NEJMoa1813599
  13. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.  https://doi.org/10.1053/j.ajkd.2007.06.008
  14. Dai S, Chen Y, Hao C, et al. Addition of roxadustat to erythropoiesis-stimulating agent (ESA) effectively corrects ESA-hyporesponsive anaemia in patients on peritoneal dialysis. J Clin Pharm Ther 2022;47:1525-1530.  https://doi.org/10.1111/jcpt.13696
  15. Chen J, Li Z, Zhang H, et al. A prospective, self-controlled pilot study of the efficacy of roxadustat for erythropoietin hyporesponsiveness in patients requiring chronic ambulatory peritoneal dialysis. J Ren Nutr 2022;32:595-604.  https://doi.org/10.1053/j.jrn.2021.09.003
  16. Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol 2016;27:1225-1233.  https://doi.org/10.1681/ASN.2015030241
  17. Hou YP, Mao XY, Wang C, et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. J Formos Med Assoc 2022;121:529-538.  https://doi.org/10.1016/j.jfma.2021.06.004
  18. Hirai K, Nonaka H, Ueda M, et al. Effects of roxadustat on the anemia and iron metabolism of patients undergoing peritoneal dialysis. Front Med (Lausanne) 2021;8:667117. 
  19. Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ 2008;179:333-337.  https://doi.org/10.1503/cmaj.071131
  20. Tanaka M, Komaba H, Fukagawa M. Emerging association between parathyroid hormone and anemia in hemodialysis patients. Ther Apher Dial 2018;22:242-245.  https://doi.org/10.1111/1744-9987.12685
  21. Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol 2010;5:576-581.  https://doi.org/10.2215/CJN.04710709
  22. Kuragano T, Kitamura K, Matsumura O, et al. ESA hyporesponsiveness is associated with adverse events in maintenance hemodialysis (MHD) patients, but not with iron storage. PLoS One 2016;11:e0147328. 
  23. Nguyen AD, McDonald JG, Bruick RK, DeBose-Boyd RA. Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs. J Biol Chem 2007;282:27436-27446.  https://doi.org/10.1074/jbc.M704976200
  24. Hwang S, Nguyen AD, Jo Y, Engelking LJ, Brugarolas J, DeBose-Boyd RA. Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. J Biol Chem 2017;292:9382-9393.  https://doi.org/10.1074/jbc.M117.788562
  25. Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol 2017;45:127-135.  https://doi.org/10.1159/000454818
  26. Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol 2017;45:380-388.  https://doi.org/10.1159/000464476
  27. Li Y, Shi H, Wang WM, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine (Baltimore) 2016;95:e3872. 
  28. Akaishi M, Hiroe M, Hada Y, Suzuki M, Tsubakihara Y, Akizawa T; KRN321 Study Group. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease . J Cardiol 2013;62:249-256.  https://doi.org/10.1016/j.jjcc.2013.04.008
  29. Suzuki M, Hada Y, Akaishi M, et al. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease. Int Heart J 2012;53:238-243.  https://doi.org/10.1536/ihj.53.238
  30. Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat Versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol 2022;33:850-866.  https://doi.org/10.1681/ASN.2020111638
  31. Charytan C, Manllo-Karim R, Martin ER, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep 2021;6:1829-1839.  https://doi.org/10.1016/j.ekir.2021.04.007
  32. Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep 2020;6:624-635.  https://doi.org/10.1016/j.ekir.2020.11.034
  33. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012;1823:1434-1443.  https://doi.org/10.1016/j.bbamcr.2012.01.014
  34. Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant 2021;36:1717-1730.  https://doi.org/10.1093/ndt/gfab051
  35. Shutov E, Sulowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant 2021;36:1629-1639.  https://doi.org/10.1093/ndt/gfab057
  36. Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES) Nephrol Dial Transplant 2021;36:1616-1628. https://doi.org/10.1093/ndt/gfab191